ArticleBMC cardiovascular disorders2026
PINP levels in patients with newly diagnosed heart failure are associated with myocardial fibrosis and clinical outcomes.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo investigate the association of Procollagen I N-Terminal Propeptide (PINP) with myocardial fibrosis (MF) and its predictive effect on major adverse cardiovascular events (MACEs) in patients with primary diagnosis of heart failure (HF).
methodsA total of 76 newly diagnosed HF patients with reduced ejection fraction were followed up for one year. Serum PINP levels and extracellular volumes (ECV) quantified by cardiac magnetic resonance(CMR) imaging at baseline were collected. MF was defined when a ECV value was greater than 28.5%. The first MACEs defined as rehospitalization and/or cardiovascular death, were recorded during the visit.
resultsThe levels of PINP in patients with MF were higher than those in patients without MF (39.90 VS 49.10 ng/ml, P = 0.030). Multivariate logistic regression analysis showed that PINP was an independent risk factor for MF (OR 1.058, 95% CI 1.018 ~ 1.098, P = 0.004). The linear regression model showed a linear correlation between the PINP levels and ECVs (R = 0.280, P = 0.014). Patients with higher PINP levels had a significant increased risk of incident MACE than those with lower PINP levels (HR 1.95, 95%CI 1.03 ~ 3.69, P = 0.033).
conclusionIn patients with newly diagnosed HF, serum PINP levels were associated with MF and an increased risk of MACEs during a one-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.